A setback yesterday for Merck, as a Food and Drug Administration advisory panel overwhelmingly recommended that the body not approve Arcoxia, a pain pill related to the ill-fated Vioxx. The FDA is expected to weigh in on April 27, and usually follows the recommendations of the advisory panel. GCI Group assists Merck with the drug.